baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

UC WAR. CALL 09/24 IDP/ DE000HD4NAM7 /

05/07/2024 21:40:09	Chg.+0.0200	Bid21:58:21	Ask21:58:21	Underlying	Strike price	Expiration date	Option type
0.4400EUR	+4.76%	0.4300 Bid Size: 10,000	0.4400 Ask Size: 10,000	BIOGEN INC. DL -,000...	260.00 -	18/09/2024	Call

GlobeNewswire 28/06 “LEQEMBI®” (Lecanemab) for the Treatment of Alzheimer’s Disease Launched in China

GlobeNewswire 24/06 TOFIDENCE™ (tocilizumab), a Biosimilar Referencing ROACTEMRA®, Approved in the European Union

GlobeNewswire 10/06 FDA Accepts Eisai’s Filing of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application f...

GlobeNewswire 03/06 Biogen and Delta Flight Products to Collaborate with Advocates and Patients to Inform the Future of ...

GlobeNewswire 30/05 Biogen Receives European Commission Approval for QALSODY® (tofersen), the First Therapy to Treat a R...

GlobeNewswire 22/05 Biogen Bolsters Late-Stage Pipeline, Expands Immunology Portfolio with Agreement to Acquire Human Im...

GlobeNewswire 21/05 Avadel Pharmaceuticals Appoints Naseem Amin, M.D. to its Board of Directors

GlobeNewswire 16/05 Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lat...

GlobeNewswire 15/05 Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (lecanemab-irmb) for Su...

GlobeNewswire 02/05 Biogen Reports Progress on Corporate Responsibility Priorities

GlobeNewswire 25/04 Biogen Receives Positive CHMP Opinion for TOFIDENCE™ (tocilizumab), a Biosimilar Referencing ROACTEM...

TeleTrader 24/04 Biogen posts Q1 revenue of $2.3 billion

GlobeNewswire 23/04 Recludix Pharma Announces the Appointment of Dr. Ajay Nirula, Accomplished Pharma Executive and Immu...

GlobeNewswire 02/04 ADARx Pharmaceuticals Appoints Dr. Chris Storgard as Chief Medical Officer

GlobeNewswire 06/03 New Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA® (nusinersen) i...

GlobeNewswire 04/03 Biogen Highlights New Data at the International Conference on Alzheimer’s and Parkinson’s Diseases (...

GlobeNewswire 23/02 Biogen’s QALSODY® (tofersen), the First Therapy to Treat Rare, Genetic Form of ALS, Received Positiv...

TeleTrader 13/02 Biogen's Q4 revenue falls 6% to $2.4 billion

GlobeNewswire 12/02 Biogen Received European Commission Approval for SKYCLARYS® (omaveloxolone), the First Therapy to Tr...

TeleTrader 12/02 Earnings preview: Robinhood, Coinbase and more

GlobeNewswire 08/02 Zymeworks Announces Appointment of Dr. Alessandra Cesano to its Board of Directors

GlobeNewswire 04/01 Stran & Company Appoints Ian Thomas Wall as Chief Information Officer

GlobeNewswire 19/12/2023 Centralized Marketing Authorizations of Generic Versions of TECFIDERA® are Revoked by the European C...

GlobeNewswire 15/12/2023 CHMP Issues Positive Opinion for Biogen’s SKYCLARYS® (omaveloxolone), the First Therapy to Treat Fri...

GlobeNewswire 14/12/2023 ZURZUVAE™ (zuranolone) CIV, a Landmark Oral Treatment for Women with Postpartum Depression (PPD), is...

UC WAR. CALL 09/24 IDP/ DE000HD4NAM7 /

If you wish to receive reply to your feedback, please provide your email address.